» Articles » PMID: 12374673

Prognostic Significance of Signal Transducer and Activator of Transcription 1 Activation in Breast Cancer

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2002 Oct 11
PMID 12374673
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Signal transducers and activators of transcription (STATs)were shown to be activated in mammary carcinoma. Because different STAT factors are likely to have different functions in these tumors, an assessment of their individual role is mandatory.

Experimental Design: In this study we have separately determined activation of STAT1, STAT3, and STAT5 by measuring their DNA binding activity and tyrosine phosphorylation in breast cancer tissue samples. The predictive value of STAT activation on relapse-free and overall survival among women who received treatment for primary breast cancer was evaluated in a retrospective study.

Results: Survival analysis demonstrated that patients with high STAT1 activation have substantially longer overall and relapse-free survival, irrespective of whether STAT1 activation was determined by its DNA binding activity (P = 0.003 and 0.010, respectively) or by its tyrosine phosphorylation (P = 0.046 and 0.011, respectively). In accordance, Cox proportional hazard regression analysis revealed an enhanced hazard of death (hazard ratio, 3.77; P = 0.018) and relapse of disease (hazard ratio, 6.55; P = 0.013) for the group of women with low STAT1 activation. After adjusting for known prognostic variables (lymph node status, stage of disease, estrogen receptor status, and cathepsin D), STAT1 activation remained an independent prognostic value. Activation of STAT3 and STAT5 DNA binding did not significantly correlate with prognosis.

Conclusion: Our study reveals a favorable and independent prognostic significance of STAT1 activation in mammary carcinoma, and is in accordance with the documented role of STAT1 in growth arrest, and in pro-apoptotic signaling pathways.

Citing Articles

Role of EGFR and FASN in breast cancer progression.

Chaturvedi S, Biswas M, Sadhukhan S, Sonawane A J Cell Commun Signal. 2023; 17(4):1249-1282.

PMID: 37490191 PMC: 10713975. DOI: 10.1007/s12079-023-00771-w.


Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy.

Han J, Wu M, Liu Z Front Immunol. 2023; 14:1190333.

PMID: 37275859 PMC: 10233742. DOI: 10.3389/fimmu.2023.1190333.


Construction of an Immune Escape-Related Signature in Clear Cell Renal Cell Carcinoma and Identification of the Relationship between IFNAR1 and Immune Infiltration by Multiple Immunohistochemistry.

Chang K, Xu F, Zhang X, Zeng B, Zhang W, Shi G Cancers (Basel). 2023; 15(1).

PMID: 36612165 PMC: 9818644. DOI: 10.3390/cancers15010169.


A pan-cancer analysis of the expression of STAT family genes in tumors and their relationship to the tumor microenvironment.

Zhou M, Zhang P, Da M, Yang R, Ma Y, Zhao J Front Oncol. 2022; 12:925537.

PMID: 36176415 PMC: 9513395. DOI: 10.3389/fonc.2022.925537.


Comprehensive analysis of the prognostic and immunotherapeutic implications of STAT family members in human colorectal cancer.

Li D, Jiao Y, Gao W, Hu S, Li D, Zhao W Front Genet. 2022; 13:951252.

PMID: 36061181 PMC: 9437353. DOI: 10.3389/fgene.2022.951252.